PubMed Health⌕ Search

Biomedical subjects

L Z Wajsman

Publications and source records attributed to L Z Wajsman.

7 recordsLinked to original sources
PubMed1983

High-dose cytoreductive therapy with autologous bone marrow transplantation in advanced malignancies.

Twenty-one patients with advanced malignancies received high-dose chemotherapy and/or radiotherapy followed by autologous bone marrow infusion. Eighteen patients (85.7%) had fever greater than or equal to 100 degrees F for a median of 6 days; 14 of these patients required broad-spectrum antibiotics for a median of 13 days. Nineteen patients (90.5%) had a granulocyte count less than 500/mm3 for a median of 11 days. Thrombocytopenia (platelet count less than 50,000/mm3) was observed in 18 patients (85.7%) for a median of 14 days. Mucositis and diarrhea were not common, occurring in six (28.6%) and seven (33.3%) patients, respectively. Of the 21 patients studied, 16 were evaluable for tumor response; there were four complete responses and four partial responses, and two patients who showed no change for variable times. Two patients have unmaintained remissions for greater than 2 years. Our response rate (complete plus partial) is 50%. Our study shows that high-dose cytoreductive therapy can be given with moderate toxicity when combined with autologous bone marrow infusion. Because responses in this group of patients are generally of short duration, we believe that patients with advanced malignancies who have had less exposure to therapy or who have a high likelihood of disease recurrence should be considered for high-dose cytoreductive therapy with autologous transplantation.

Adult↗
PubMed1982

Intermittent hemodialysis therapy in the cancer patient.

The occurrence of renal failure in the cancer patient presents a series of medical, technical, philosophical, and logistic problems that are rarely found in other patient population groups. In a review of 70 cancer patients requiring intermittent hemodialysis therapy at Roswell Park Memorial Institute over the last 6 years for acute renal failure, 46 (65.7%) of the patients were salvaged from renal failure to allow the use of further therapeutic modalities for their neoplastic disease. Patient survival after successful intermittent hemodialysis therapy was comparable to that expected in the nonazotemic cancer patients submitted to similar anticancer therapy. Hemodialysis should, therefore, be considered and offered in selected cancer patients in acute renal failure.

Acute Kidney Injury↗
PubMed1981

Carcinoplacental isoenzyme (Regan) in carcinoma of the prostate. National Prostatic Cancer Project.

Serum samples were examined for the placental-like "Regan" isoenzyme of alkaline phosphatase in two groups of patients with advanced cancer of the prostate from clinical trials of the National Prostatic Cancer Project. In the first group, 98 samples from 76 patients over three consecutive months revealed elevated isoenzyme activity in 14 (18%) of the patients, a frequency similar to those reported for some other tumor types. Four of these patients whose serum demonstrated the "Regan" isoenzyme had samples taken more than once, and their sera had negative readings when taken a month or more before or after the sample that was positive for the isoenzyme. Comparisons of general disease and patient characteristics for patients whose sera were positive or negative for Regan isoenzyme revealed no demonstrable relationships. The second group consists of 72 samples received from 52 study patients with metastatic lesions under treatment from August 1, 1979 to November 16, 1979. Fifteen patients had sufficient serial values. In this study to date, the relationship with clinical response to treatment is inconclusive, although elevated levels of the isoenzyme appear to occur in patients with metastatic disease with bony lesions that are clinically in progression, as well as in those apparently responding to chemotherapy.

Aged↗
PubMed1981

Chemotherapy in metastatic, hormone refractory prostatic cancer using chlorambucil in combination with prednisolone versus conjugate, prednimustine (Leo 1031).

Chlorambucil plus prednisolone were administered to 11 patients with metastasis hormone refractory prostatic cancer, and the results were contrasted with a previously reported series of 23 similar patients treated with the chemical conjugate of these two agents, known as prednimustine or Leo 1031. The conjugated form of treatment (Leo 1031) had a limited therapeutic advantage, in that 3 patients experienced shrinkage of an enlarged prostate, 2 of whom also had elevated acid phosphatase levels return to normal and 5 others experienced only subjective improvement. There were, however, more adverse side effects in this group than those noted in patients treated with the combination of agents. Patients treated with the combination of drugs experienced no appreciable tumor shrinkage and none had acid phosphatase return to normal, although some reduction was noted in 8 of 11 patients who had elevated levels initially. Two of the 11 patients were considered stable for twelve months and one other remained ambulatory with mild pain for six months. Thus, to the degree that these studies permit, it is judged that the conjugated agent may have some limited therapeutic advantage not observed when the unconjugated agents were used.

Aged↗
PubMed1980

Value of new fluorescent immunoassay for human prostatic acid phosphatase in prostate cancer.

A new solid phase fluorescent immunoassay for human prostatic acid phosphatase in prostatic cancer has been evaluated. This technique is rapid, quantitative, and sensitive. In more than 133 patients studied by the National Prostatic Cancer Project, positive results were obtained in patients with localized, nonmetastatic disease as confirmed by clinical testing, surgical staging, and careful inspection of all pelvi lymph node material in appropriate cases. That this can occur even in Stage A2 patients may alter current concepts on the staging or, even further, on the therapy of prostatic cancer.

Acid Phosphatase↗